Intellia Therapeutics (NTLA) Assets Average (2016 - 2026)
Intellia Therapeutics (NTLA) reported Assets Average of $800.5 million for Q1 2026, down 26.47% year-over-year from $1.1 billion in Q1 2025, and down 9.42% on a QoQ basis from $883.7 million in Q4 2025.
Intellia Therapeutics (NTLA) has 11 years of Assets Average data on file, last reported at $800.5 million in Q1 2026.
- Quarterly Assets Average fell 26.47% year-over-year to $800.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $800.5 million (down 26.47% YoY) and the FY2025 annual result came in at $1.0 billion, down 18.41% from the prior year.
- Assets Average declined to $800.5 million in Q1 2026 per NTLA's latest filing, from $883.7 million in the prior quarter.
- Across five years, Assets Average topped out at $1.5 billion in Q1 2023 and bottomed at $800.5 million in Q1 2026.
- The 5-year median for Assets Average is $1.2 billion (2024), against an average of $1.2 billion.
- The widest annual swing landed in 2022, when Assets Average jumped 79.24%; it then declined 26.47% in 2026.
- Tracing NTLA's Assets Average over 5 years: stood at $1.3 billion in 2022, then slipped by 2.31% to $1.3 billion in 2023, then retreated by 7.07% to $1.2 billion in 2024, then retreated by 25.25% to $883.7 million in 2025, then retreated by 9.42% to $800.5 million in 2026.
- Per Business Quant, the three latest NTLA Assets Average figures stand at $800.5 million (Q1 2026), $883.7 million (Q4 2025), and $912.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Intellia Therapeutics | 1.63 Bn | 1.63 Bn | - | 800.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 800.45 Mn |
| Dec 31, 2025 | 883.70 Mn |
| Sep 30, 2025 | 912.08 Mn |
| Jun 30, 2025 | 942.53 Mn |
| Mar 31, 2025 | 1.09 Bn |
| Dec 31, 2024 | 1.18 Bn |
| Sep 30, 2024 | 1.18 Bn |
| Jun 30, 2024 | 1.23 Bn |
| Mar 31, 2024 | 1.28 Bn |
| Dec 31, 2023 | 1.27 Bn |
| Sep 30, 2023 | 1.28 Bn |
| Jun 30, 2023 | 1.37 Bn |
| Mar 31, 2023 | 1.47 Bn |
| Dec 31, 2022 | 1.30 Bn |
| Sep 30, 2022 | 1.10 Bn |
| Jun 30, 2022 | 1.16 Bn |
| Mar 31, 2022 | 1.25 Bn |
| Dec 31, 2021 | 1.31 Bn |
| Sep 30, 2021 | 1.00 Bn |
| Jun 30, 2021 | 694.57 Mn |
| Mar 31, 2021 | 696.61 Mn |
| Dec 31, 2020 | 567.44 Mn |
| Sep 30, 2020 | 474.69 Mn |
| Jun 30, 2020 | 402.79 Mn |
| Mar 31, 2020 | 324.52 Mn |
| Dec 31, 2019 | 340.46 Mn |
| Sep 30, 2019 | 349.54 Mn |
| Jun 30, 2019 | 348.40 Mn |
| Mar 31, 2019 | 345.84 Mn |
| Dec 31, 2018 | 334.27 Mn |
| Sep 30, 2018 | 330.51 Mn |
| Jun 30, 2018 | 349.66 Mn |
| Mar 31, 2018 | 367.89 Mn |
| Dec 31, 2017 | 312.70 Mn |
| Sep 30, 2017 | 257.07 Mn |
| Jun 30, 2017 | 272.12 Mn |
| Mar 31, 2017 | 289.12 Mn |
| Dec 31, 2016 | 300.22 Mn |
| Sep 30, 2016 | 306.05 Mn |
| Jun 30, 2016 | 193.08 Mn |
| Mar 31, 2016 | 78.84 Mn |